Keywords
Diabetic ketosis
Metabolic acidosis
Hiperglycemic
Ketonemia
Insulin
How to Cite
Abstract
Background: Diabetic ketoacidosis (DKA) is frequently in the emergency department (ED). It is an acute complication of diabetes, with a risk of potentially fatal events and increased morbidity in this patient group. This complication is generally clinically characterized by hyperglycemia, metabolic acidosis, and the finding of ketonemia due to an absolute insulin deficiency.
Purpose: However, there are exceptions within the definition of ketoacidosis, and elevated blood glucose levels are not always present. This complicates the diagnosis, delays management, and increases the morbidity and mortality associated with this condition, highlighting the importance of its timely identification
Case presentation: The following presentation presents a 63-year-old patient admitted to the ED with diabetes mellitus being managed with sitagliptin who developed euglycemic DKA.
Discussion and conclusion: In general, diabetic ketoacidosis is an atypical but potentially serious presentation that may go unnoticed due to the absence of marked hyperglycemia; therefore, a thorough clinical history is essential for its suspicion.
References
Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, et al. Hyperglycemic crises in diabetes. Diabetes Care. 2004;27(supl. 1):S94-102. https://doi.org/10.2337/diacare.27.2007.s94
Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157-60. https://doi.org/10.1016/j.ajem.2021.02.015
Modi A, Agrawal A, Morgan F. Euglycemic diabetic Ketoacidosis: a review. Curr Diabetes Rev. 2017;13(3):315-21. https://doi.org/10.2174/1573399812666160421121307
Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753-62. https://doi.org/10.4158/ep161292.ps
Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020;20(7):25. https://doi.org/10.1007/s11892-020-01307-x
Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9-14. https://doi.org/10.1016/j.ejim.2019.03.014
Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis Br Med J. 1973;2(5866):578-80. https://doi.org/10.1136/bmj.2.5866.578
Brown DX, Evans M. Choosing between GLP-1 receptor agonist and DPP-4 inhibitors: a pharmacological perspective. J Nutr Metabol. 2012;2012:381713. https://doi.org/10.1155/2012/381713
Carramiñana Barrera FC. Seguridad de los inhibidores de la dipeptidil peptidasa 4. Semergen. 2018;44(supl. 1):10-7. http://dx.doi.org/10.1016/S1138-3593(18)30370-8
Jeong SH, Vorachitti M, Fuentes F. A case of euglycemic diabetic ketoacidosis (DKA), influenza, and a dipeptidyl peptidase-4 (DPP-4) inhibitor. Cureus. 2023;15(5):e39012. https://doi.org/10.7759/cureus.39012
Chicote-Álvarez E, Camino-Ferró H, Mainar-Gil I, Vilella-Llop LÁ, Ruiz de la Cuesta-López M, Lizama-Gómez NG. Cetoacidosis diabética euglucémica en paciente gestante con infección por SARS-CoV-2: reporte de caso. Acta Colomb Cuid Intensivo. 2022;23(1):78-81. https://doi.org/10.1016/j.acci.2022.09.002
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Revista Colombiana de Endocrinología, Diabetes & Metabolismo